Glow Peptide Stack side effects

What is known about Glow side effects

No safety data exist for the three-peptide blend.¹ An FDA complaint database holds two reports about "blended TB-500 and BPC-157", and neither included a safety assessment.³ A search of FDA's adverse event database for TB-500 through March 26, 2025 returned no reports.³ A 2026 sports medicine review calls rigorous human safety data for these unapproved peptides scarce and warns of potential for serious harm.⁴

The lists below group what has been reported by the strength of the evidence. They run from case reports in people, to small human studies, to animal findings, to risks no study has measured.

Reported in people

Case reports to FDA (rate unknown)

• Skin and gum darkening. A 40-year-old woman injected a product labeled for research purposes only, containing BPC-157 and TB-500, under the skin twice daily.² After one week she developed diffuse skin darkening (hyperpigmentation) and darkened gums. On rechallenge two weeks later, the identical reaction returned, and it did not recur once she stopped.² FDA judged the reaction likely due to the product, but because the product held two peptides, it could not tie the reaction to BPC-157 alone.²
• Injection-site reaction and shortness of breath. Both were also reported to FDA for BPC-157 products. FDA says it is unclear whether BPC-157 caused any of these events.²

Seen in small human studies

• BPC-157 by enema. In a placebo-controlled study of 32 healthy volunteers, 24 of whom received BPC-157, headache and flatulence were the most frequent adverse events. They occurred with no obvious difference in frequency or severity from placebo, according to the meeting abstracts FDA summarized.²
• BPC-157 across studies. A 2026 systematic review of three small studies (30 people) found no treatment-related adverse events. It judged the studies to be of poor methodological quality.⁵ FDA adds that the human BPC-157 studies were short and small.²
• Thymosin beta-4 by vein, not TB-500. In a placebo-controlled trial in 40 healthy adults, adverse events were infrequent and mild or moderate, with no dose-limiting toxicities or serious adverse events.⁶
• GHK-Cu on the skin. In the 18-adult eyebrow trial of a 2% serum, no serious adverse effects or allergic reactions were reported.⁷⁸ In a 6-month trial in 45 men of a hair solution combining GHK (not GHK-Cu) with 5-aminolevulinic acid, no adverse events occurred in any group.⁹

Seen in animal studies

• Clotting and liver changes (BPC-157). In 28-day studies of BPC-157 injected into muscle, published in 2020, FDA describes a shorter clotting test time (aPTT) in rats and a longer one in dogs. It also lists liver-related signals: higher ALT, glucose and triglycerides.²
• The 2020 study's own summary (BPC-157). Its authors called BPC-157 well tolerated, with no serious toxicity in mice, rats, rabbits or dogs. They reported mild irritation in a local tolerance test, and lower creatinine in dogs at 2 mg/kg (not at lower doses) that resolved within 2 weeks off treatment.¹⁰
• Gaps (BPC-157). BPC-157 was not mutagenic in standard tests, but FDA found no carcinogenicity studies.²
• Gaps (TB-500). FDA found no nonclinical toxicity studies of TB-500 at all.³
• GHK-Cu. A 2026 review says animal studies have not shown relevant toxicity for systemic GHK-Cu.¹¹

Possible risks no study has measured

Regulators and reviewers name these risks for injected peptides like Glow's ingredients. None has been measured for the blend, so how often they occur is unknown.

• Immune reactions. FDA warns that injected TB-500 and BPC-157 may pose a significant risk of immunogenicity, which aggregation and impurities can amplify.³² Outcomes range from antibodies with no symptoms to life-threatening reactions. Antibodies could even neutralize the body's own matching peptide.³ In general, injection under the skin carries more immunogenicity than injection into muscle or a vein.³
• Copper imbalance. A 2026 review warns that systemic delivery of copper-binding peptides can disturb copper balance, causing oxidative stress and possible liver toxicity.¹² No controlled trial of injected GHK-Cu has tested this.¹²
• Tumor growth (theoretical). A 2026 review notes that BPC-157's VEGFR2 signaling, which drives blood-vessel growth, could feed an undiagnosed tumor.¹² Health Canada lists growth of cancerous tumours, blood clots, and liver or kidney damage among possible risks of unauthorized peptide drugs.¹³
• Infection and contamination. Health Canada warns that unauthorized injectable peptides can lead to infections, allergic reactions and other serious complications.¹³

Warnings

• Safety in people is unknown. For BPC-157, FDA says it lacks sufficient information to know whether the peptide would cause harm in people.¹⁴ For TB-500, FDA concluded that potential safety risks in humans are unknown.³
• Athletes. Both BPC-157 and TB-500 are banned in sport under WADA's 2026 list.¹⁵
• Canada. Health Canada advises consumers against using unauthorized injectable peptides.¹³

Related pages

What is Glow Peptide Stack? covers the blend's contents and regulatory status. Glow Peptide Stack dosage explains why no human dose exists, and Glow Peptide Stack benefits and uses lists what studies report. For one ingredient, see TB-500 side effects; for a related blend, see KLOW Peptide Blend side effects. General risk and handling: Peptide safety basics. Vial contents and storage: Glow Peptide Stack for sale.